The 9th International Neoantigen Summit 2026 focuses on advancing neoantigen-based cancer vaccines and personalized immunotherapy by integrating clinical insights, innovative technologies, and scalable strategies to improve patient outcomes.
Key Topics
Personalized mRNA neoantigen vaccine platforms and clinical data integration
Immune response monitoring and identification of therapy responders
Clinical trial cost challenges and optimization strategies
Mutational landscape analysis in individualized neoantigen therapies
Neoantigen discovery using AI, bioinformatics, and immunopeptidomics
HLA profiling and genotype-based predictive biomarkers
Tumor-derived approaches for personalized cancer vaccine development
Limitations and advancements in immunopeptidomics technologies
Predictive modeling and T-cell targeting optimization
Alternative predictors of immune response beyond binding affinity
DNA-encoded neoantigen vaccines and immunogenicity data
Combination therapies and synergistic treatment strategies
Clinical translation of neoantigen therapies across cancer types
Advantages and limitations of combination immunotherapy approaches
AI-driven neoantigen selection and validation methods
Clinical trial design, setup, and regulatory considerations
Next-generation modalities for neoantigen targeting
Dark genome exploration and novel neoantigen classes
HLA-G-presented peptides and new targets for solid tumors
Scalable manufacturing of personalized neoantigen vaccines
Balancing personalized and off-the-shelf immunotherapy approaches
Neoantigen peptide therapies in glioblastoma and other cancers
Cancer prevention strategies using neoantigen vaccines
Streamlining clinical development and improving cost efficiency
Real-world data analysis of personalized neoantigen treatments
Tumor-trained lymphocyte therapies and early-phase clinical trials
